COMMISSION ON HUMAN MEDICINES [FOI Request]

The Commission on Human Medicines (CHM) is a committee of the UK's Medicines and Healthcare products Regulatory Agency. It was formed in October 2005 by the amalgamation of the Medicines Commission and the Committee on Safety of Medicines.

The duties of the Commission which came into being on 30 October 2005, are set out in Section 3 of the Medicines Act 1968, as amended by the Medicines (Advisory Bodies) Regulations 2005 and include the following:

• to advise Ministers on matters relating to human medicinal products (except those that fall under the remit of Advisory Board on the Registration of Homoeopathic Products (ABRH) and Herbal Medicines Advisory Committee (HMAC))

• to advise the Licensing Authority (LA) where the LA has a duty to consult the Commission or where the LA chooses to consult the Commission including giving advice in relation to the safety, quality and efficacy of human medicinal products

• to consider representations made in relation to the Commission’s advice (either in writing or at a hearing) by an applicant or by a licence or marketing authorisation holder

• to promote the collection and investigation of information relating to adverse reactions for human medicines (except for those products that fall within the remit of ABRH or HMAC) for the purposes of enabling such advice to be given.

The Chair of the PATIENT INFORMATION EXPERT ADVISORY GROUP is Ms Joanne Rule.

Her DECLARED CURRENT PERSONAL AND NON- PERSONAL INTERESTS IN THE PHARMACEUTICAL INDUSTRY AS FOLLOWS:

3m Pharmaceuticals
Amgen Limited
Astrazeneca Plc
Baxter Healthcare Ltd
Bayer Plc
Bristol Myers
Cambridge Laboratories
Chiron UK Ltd
Eli Lilly & Co Ltd
Glaxo Smith Kline
Ipsen Ltd
Merck Pharmaceuticals
Napp
Novartis Pharmaceuticals
UK Ltd
Ortho Biotech
Pfizer Ltd
Pierre Fabre Ltd
Platon Medical
Roche Products Ltd
Sanofi Aventis
Schering Health
Schering Plough
Wyeth Laboratories

Q1. I would like to know what advice [if any] Ms Joanne Rule has given ministers regarding Seroxat?

Q2. I would like to know what advice [if any] Ms Joanne Rule has given to the Licensing Authority regarding the safety, quality and efficacy of Seroxat?

Q3. I would like to know if Ms Joanne Rule would be prepared to meet with a group of Seroxat campaigners/advocates/activists [call them what you will] at her earliest convenience?

Q4. I would like to know what Ms Joanne Rule has done to promote the collection and investigation of adverse reactions for Seroxat.

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON